In recent years, prevalence of multidrug resistance (MDR) in Pseudomonas aeruginosa (P. aeruginosa) has been noticed with high morbidity and mortality. Aim of the present study was to determine the impact of Mr. Trivedi’s biofield treatment on MDR clinical lab isolates (LS) of P. aeruginosa. Five MDR clinical lab isolates (LS 22, LS 23, LS 38, LS 47, and LS 58) of P. aeruginosa were taken and divided into two groups i.e. control and biofield treated. Control and treated group were analyzed for antimicrobial susceptibility pattern, minimum inhibitory concentration (MIC), biochemical study and biotype number using MicroScan Walk-Away® system. The analysis was done on day 10 after biofield treatment as compared with control group. Antimicrobial sensitivity assay showed 60% alteration in sensitivity of tested antimicrobials in MDR isolates of P. aeruginosa after biofield treatment. MIC results showed an alteration in 42.85% tested antimicrobials out of twenty eight after biofield treatment in five isolates of MDR P. aeruginosa. Biochemical study showed a 48.48% change in tested biochemical reactions out of thirty three as compared to control. A significant change in biotype numbers was reported in three clinical lab isolates of MDR P. aeruginosa out of five, after biofield treatment as compared to respective control. On the basis of changed biotype number (7302 0052) in biofield treated LS 23, new organism was identified as Citrobacter freundii as compared to control (0206 3336). A very rare biotype number (7400 4263) was found in biofield treated LS 38, as compared to control (0206 3736). Study results suggest that biofield treatment on lab isolates of MDR P. aeruginosa has significant effect on the antimicrobial sensitivity, MIC values, biochemical reactions and biotype number. Biofield treatment might prevent the emergence of absolute resistance pattern of useful antimicrobials against MDR isolates of P. aeruginosa.
1. Nathwani D, Raman G, Sulham K, Gavaghan M, Menon V (2014) Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis. Antimicrob Resist Infect Control 3: 32.
2. Acar JF (1997) Consequences of bacterial resistance to antibiotics in medical practice. Clin Infect Dis 24: S17-18.
3. Poole K (2011) Pseudomonas aeruginosa: resistance to the max. Front Microbiol 2: 65.
4. Kerr KG, Snelling AM (2009) Pseudomonas aeruginosa: a formidable and ever-present adversary. J Hosp Infect 73: 338-344.
5. Rossolini GM, Mantengoli E (2005) Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa. Clin Microbiol Infect 11: 17-32.
6. Gaynes R, Edwards JR; National Nosocomial Infections Surveillance System (2005) Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis 41: 848-854.
7. Poole K (2005) Aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 49: 479-487.
8. Strateva T, Yordanov D (2009) Pseudomonas aeruginosa - a phenomenon of bacterial resistance. J Med Microbiol 58: 1133-1148.
9. Ergin C, Mutlu G (1999) Clinical distribution and antibiotic resistance of Pseudomonas species. East J Med 4: 65-69.
10. Lucchetti G, de Oliveira RF, Gonçalves JP, Ueda SM, Mimica LM, et al. (2013) Effect of Spiritist "passe" (Spiritual healing) on growth of bacterial cultures. Complement Ther Med 21: 627-632.
11. Benor DJ (2002) Energy medicine for the internist. Med Clin North Am 86: 105-125.
12. Yount G, Patil S, Dave U, Alves-dos-Santos L, Gon K, et al. (2013) Evaluation of biofield treatment dose and distance in a model of cancer cell death. J Altern Complement Med 19: 124-127.
13. Jonas WB, Crawford CC (2003) Science and spiritual healing: a critical review of spiritual healing, "energy" medicine, and intentionality. Altern Ther Health Med 9: 56-61.
14. Einstein A (1905) Does the inertia of a body depend upon its energy-content. Ann Phys 18: 639-641.
15. Trivedi MK, Patil S, Shettigar H, Gangwar M, Jana S (2015) Antimicrobial sensitivity pattern of Pseudomonas fluorescens after biofield treatment. J Infect Dis Ther 3: 222.
16. Trivedi MK, Patil S, Shettigar H, Bairwa K, Jana S (2015) Phenotypic and biotypic characterization of Klebsiella oxytoca: An impact of biofield treatment. J Microb Biochem Technol 7: 203-206.
17. Trivedi MK, Bhardwaj Y, Patil S, Shettigar H, Bulbule A (2009) Impact of an external energy on Enterococcus faecalis [ATCC-51299] in relation to antibiotic susceptibility and biochemical reactions-An experimental study. J Accord Integr Med 5: 119-130.
18. Trivedi MK, Nayak G, Patil S, Tallapragada RM, Latiyal O (2015) Studies of the atomic and crystalline characteristics of ceramic oxide nano powders after bio field treatment. Ind Eng Manage 4:161.
19. Trivedi MK, Tallapragada RR (2008) A transcendental to changing metal powder characteristics. Met Powder Rep 63: 22-29, 31.
20. Dabhade VV, Tallapragada RR, Trivedi MK (2009) Effect of external energy on atomic, crystalline and powder characteristics of antimony and bismuth powders. Bull Mater Sci 32: 471-479.
21. Lenssen AW (2013) Biofield and fungicide seed treatment influences on soybean productivity, seed quality and weed community. Agricultural Journal 8: 138-143.
22. Nayak G, Altekar N (2015) Effect of biofield treatment on plant growth and adaptation. J Environ Health Sci 1: 1-9.
23. Shinde V, Sances F, Patil S, Spence A (2012) Impact of biofield treatment on growth and yield of lettuce and tomato. Aust J Basic Appl Sci 6: 100-105.
24. Sances F, Flora E, Patil S, Spence A, Shinde V (2013) Impact of biofield treatment on ginseng and organic blueberry yield. Agrivita J Agric Sci 35: 22-29.
25. Fader RC, Weaver E, Fossett R, Toyras M, Vanderlaan J, et al. (2013) Multilaboratory study of the biomic automated well-reading instrument versus MicroScan WalkAway for reading MicroScan antimicrobial susceptibility and identification panels. J Clin Microbiol 51: 1548-1554.
26. Orrett FA (2004) Antimicrobial susceptibility survey of Pseudomonas aeruginosa strains isolated from clinical sources. J Natl Med Assoc 96: 1065-1069.
27. Chen HY, Yuan M, Livermore DM (1995) Mechanisms of resistance to beta-lactam antibiotics amongst Pseudomonas aeruginosa isolates collected in the UK in 1993. J Med Microbiol 43: 300-309.
28. Mohanasoundaram KM (2011) The antibiotic resistance pattern in the clinical isolates of Pseudomonas aeruginosa in a tertiary care hospital; 2008-2010 (A 3 year study). J Clin Diagn Res 5: 491-494.
29. Obritsch MD, Fish DN, MacLaren R, Jung R (2005) Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 25: 1353-1364.
30. Kanj SS, Kanafani ZA (2011) Current concepts in antimicrobial therapy against resistant Gram-negative organisms: Extended-spectrum ß-Lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa. Mayo Clin Proc 86: 250-259.
31. Zavascki AP, Carvalhaes CG, Picão RC, Gales AC (2010) Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy. Expert Rev Anti Infect Ther 8: 71-93.
32. Arai T, Otake M, Enomoto S, Goto S, Kuwahara S (1970) Determination of Pseudomonas aeruginosa by biochemical test methods. II. Acylamidase test, a modified biochemical test for the identification of Pseudomonas aeruginosa. Jpn J Microbiol 14: 279-284.
33. Hintz KJ, Yount GL, Kadar I, Schwartz G, Hammerschlag R, et al. (2003) Bioenergy definitions and research guidelines. Altern Ther Health Med 9: A13-A30.
Cite this work
Researchers should cite this work as follows:
Trivedi MK, Branton A, Trivedi D, Nayak G, Shettigar H, et al. (2015) Antibiogram of Multidrug-Resistant Isolates of Pseudomonas aeruginosa after Biofield Treatment. J Infect Dis Ther 3: 244. doi:10.4172/2332-0877.1000244